Trasylollawsuitcenter.com

Please Login or Register

by: Steve Fields656
Total views: 35
Word Count: 435

Trasylollawsuitcenter.com

Bayer's problems are increasing with a growing number of Trasylol lawsuits being filed following increasing reports of the drug's serious side effects. Trasylol has recently been linked to a higher risk of kidney failure, heart attack, and death in the five years following a patient undergoing bypass heart surgery. Aprotinin is manufactured by Bayer under the brand name Trasylol. Over the past several years Trasylol sales continued to increase even though studies indicated serious Trasylol kidney damage side effects.
In 1993, Trasylol (also known as “aprotinin”) received approval from the FDA for use in certain heart bypass surgeries. Trasylol is used to reduce the amount of blood a patient loses both during and after a surgery. However, there was increasing controversy regarding the ongoing use of Trasylol, and in February of 2006, the FDA issued a public health advisory warning physicians to limit use of Trasylol. After mounting pressure, Bayer finally pulled Trasylol from the market in November 2007.
In 2006, the FDA learned that Bayer had knowledge of a study showing the dangers of Trasylol. The damaging data from Bayer’s study indicated that Trasylol increases a patient’s risks of death, stroke, congestive heart failure, and kidney failure. This data was comparable to an earlier study that indicated the administration of Trasylol during surgery dramatically increases a patient’s risks of life-threatening complications and death. This earlier study showed Trasylol use during surgery results in a 181% increased risk of stroke or encephalopathy, a 55% increased risk of heart attack or heart failure, and an over 200% increased risk of kidney failure.
In addition to the new information regarding the drug’s life-threatening risks, Trasylol studies showed that it may actually be less effective than other drugs that were available before Trasylol. These alternative drugs are generics that were cheaper, and more importantly did not pose the same life-threatening dangers to patients. Since these generics were readily available, the use of Trasylol imposed substantial and unnecessary risks on patients.
Dr. Dennis Mangano, the lead author of the important NEJM Trasylol side effects study, has noted that Trasylol problems occurred more frequently than those associated with the drug Vioxx. Dr. Mangano states, "In fact our findings raise even more troubling concerns, for:
(1) aprotinin has been on the market for three times as long as Vioxx, yet few comprehensive safety studies have been conducted since approval;
(2) the life-threatening complications with aprotinin found here occurred far more frequently than those with Vioxx; and
(3) far less expensive generic alternatives to aprotinin which are equally effective in limiting bleeding have been available, but have been underused."

About the Author

Steve Fields is a Minneapolis, Minnesota attorney representing clients in Trasylol lawsuits throughout the United States. The firm’s practice includes pharmaceutical litigation, product liability litigation, wrongful death, car and truck accidents, disability and workers compensation. Find more information about Minnesota Pharmaceutical Drug Lawyers here.

Rating: Not yet rated